



European Society for Blood and
Marrow Transplantation

Cellular Therapy & Immunobiology Working Party

Chair: Chiara Bonini

Secretary: Christian Chabannon

Subcommittee Leaders:

Immune Tolerance: Francesco Dazzi

Cord Blood Immunobiology: Annalisa Ruggeri

Cancer Immunotherapy: Attilio Bondanza

Transplant Immunobiology: Antoine Toubert

Immunogenetics: Katharina Fleischhauer & Vanderson Rocha

Mission Statement CTIWP

To understand and exploit the biological including immunological events occurring upon haematopoietic stem cell transplantation at large, and to implement modern cellular therapies based on cell and gene engineering approaches to improve transplantation outcomes.

The CTIWP aims at fostering cellular therapy in Europe, through a continuous crosstalk between basic science findings, transplant immunobiology observations and implementation of cellular manufacturing approaches designed to answer unmet medical needs.

NK Cell Allo-Reactivity

In collaboration with PDWP & ALWP

CALL FOR DATA

The role of donor vs. recipient NK cell allo-reactivity in haploidentical hematopoietic transplantation for AML and ALL

PI's: A. Velardi, L. Ruggeri

Donor-versus-recipient NK cell allo-reactivity is a key therapeutic element in the success of HLA haplotype mismatched ("haploidentical") hematopoietic stem cell transplants for acute myeloid leukemia. The role of NK cell allo-reactivity will be assessed separately in T cell depleted and T cell replete transplants in patients with 1) AML or ALL in any remission; and 2) AML or ALL in chemo-resistant relapse.

Current status:

- Participating centers: N=10 Patients collected: 215
- RECRUITMENT CLOSED**

Participating sites please send in your data

MSC Survey

There are many differences in the production of MSC's. With this survey we are testing the feasibility of harmonizing MSC manufacturing across Europe. The overall sequential plan would be:

1. To obtain names of Centres who treated GvHD with MSC
2. To prepare and send a survey on manufacturing
3. To agree a set of assays to compare cells produced at different sites
4. To obtain 3 samples from 3 different donors from each site and perform the analyses

Current status

Currently 9 sites have agreed to contribute to the survey on MSC manufacturing. The questionnaires have been sent and are awaiting responses.

Interested in participating → contact CTIWPEbmt@lumc.nl

CTIWP/CMWP Educational Course

Come of Age... Immunotherapy for Multiple Myeloma

A Joint educational symposium of the
Cellular Therapy and Immunobiology Working Party (CTIWP)
and the
Chronic Malignancies Working Party (CMWP)

Berlin, Germany
September 30 – October 01, 2016

Retrospective Studies

These studies are combined within one questionnaire.
In collaboration with PDWP & ALWP

The role of parent/child and sibling/sibling immune interactions (Inherited Paternal vs Non-inherited Maternal Antigens) in clinical outcomes after haploidentical transplantation for leukemia under diverse protocols

PI's: J.J. van Rood, F.H.J. Claas, M. Oudshoorn, D. Roelen, A. Velardi

Identifying immunological biomarkers predicting clinical outcome after haploidentical stem cell transplantation under diverse protocols

PI's: A. Bondanza, C. Bonini, A. Toubert, A. Velardi

Manuscript preparation in progress

State of the database of HLA high resolution typing
in the unrelated HSCT setting"

PI's: V. Rocha, K. Fleischhauer

Feasibility performed

Cellular Therapy Registry

This a joined effort with STWP, ADWP and IEWP

There is an urgent need to register data on patients undergoing cellular therapy in Europe. Several surveys clearly indicate that cellular therapy is increasingly applied, and no specific registry have been set up, up to now, to consistently collect numbers, nor clinical outcomes.

The CTIWP is implementing an upgrade to the EBMT registry forms which will improve the EBMT ability to collect additional and high-quality clinical and biological information from patients undergoing standard HSCT alone or combined with innovative cellular therapy and cell-based gene therapy.

Timelines:

Cell Therapy Registry – Med-A

April 2016: Cellular Therapy Registry Med A Finalized

Summer 2016: Testing and implementation

Fall 2016: Go live

Meetings EBMT Valencia

Cell Therapy day

MONDAY, April 04, 2016

CTIWP Business Meeting

Tuesday, April 05, 07:00-09:00
Room: 3G

CTIWP Session

Tuesday, April 05, 11:00-12:30
Room: B6

CTIWP Data Office

For participation in, or information on CTIWP studies, please contact the CTIWP at the EBMT Data Office in Leiden, The Netherlands;

Statistician: Dimitris Ziagos
Study coordinator: Steffie van der Werf
Data manager: Sofie Terwel

CTIWPEBMT@LUMC.NL

